Medicare Enrolled

Dr. Amparo Gordian, MD

Rheumatology · Bradenton, FL
Practice pattern: Mixed Practice — Diverse clinical practice across multiple procedure types
Low-engagement
4900 MANATEE AVE W STE 201, Bradenton, FL 34209
9417465200
In practice since 2007 (18 years)
NPI: 1205039997 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Gordian from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Gordian? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Gordian

Dr. Amparo Gordian is a rheumatology specialist in Bradenton, FL, with 18 years of NPI registration. Based on federal Medicare data, Dr. Gordian performed 262,391 Medicare services across 1,725 unique beneficiaries.

Between the years covered by Open Payments, Dr. Gordian received a total of $9,790 from 39 pharmaceutical and/or device companies across 501 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in rheumatology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Gordian is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 18 years in practice ▲ Top 4% volume in FL $9,790 industry payments

Florida License Status

FL DOH · MQA
1
Active license
None
Board action on record
0
Recent admin complaints
Profession License # Status Expires Board Action
Medical Doctor 149438 Clear January 31, 2027
Data from Florida Department of Health Medical Quality Assurance. License records are public under Chapter 119, Florida Statutes. Verify directly on FL DOH →

Medicare Practice Summary

Medicare Utilization ↗
262,391
Medicare services
Top 4% in FL for rheumatology
1,725
Unique beneficiaries
$12
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~14,577 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Certolizumab injection (Cimzia)
An injection of certolizumab pegol administered under the direct supervision of a physician.
90,800 $4 $20
Tocilizumab injection (Actemra) 58,731 $5 $10
Golimumab infusion (Simponi Aria)
Administration of golimumab medication directly into a vein. This code specifies the dosage amount of 1 milligram for intravenous delivery.
52,294 $10 $50
Abatacept infusion (Orencia)
An injection of abatacept administered under the direct supervision of a physician. This code is used for Medicare when the drug is not self-administered.
32,701 $34 $100
Denosumab injection (Prolia/Xgeva) 7,921 $18 $28
Romosozumab injection (Evenity) for osteoporosis 5,040 $8 $12
Rituximab injection, 10 mg
Administration of a 10 mg dose of rituximab medication via injection.
4,908 $64 $175
Belimumab injection, 10 mg
An injection of belimumab, a medication administered at a dose of 10 mg.
3,712 $40 $83
Infliximab infusion (Remicade)
An injection of infliximab, excluding biosimilar versions, administered in a 10 mg dose.
3,170 $26 $110
Intravenous infusion, 1 hour or less
Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less.
752 $48 $100
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
734 $87 $289
Drug injection, under skin or into muscle
A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle.
617 $11 $30
Intravenous chemotherapy infusion, 1 hour or less
Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete.
305 $98 $550
Additional hour of intravenous chemotherapy
This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period.
155 $21 $150
Zoledronic acid injection, 1 mg
An injection of zoledronic acid administered at a dose of 1 mg.
140 $6 $50
New patient office visit (45-59 min)
An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter.
122 $116 $350
Intravenous injection of additional new drug or substance
Administration of an additional new medication or substance directly into a vein.
72 $12 $34
Methylprednisolone injection, up to 125 mg
An injection of methylprednisolone sodium succinate, a corticosteroid medication, with a dosage of up to 125 mg.
63 $4 $20
Office visit, established patient, complex (40-54 min)
An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter.
49 $136 $282
Non-hormonal chemotherapy injection
This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue.
38 $55 $150
Office visit, established patient (20-29 min)
An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition.
34 $65 $200
New patient office visit, complex (60-74 min) 33 $160 $375
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
34.0% high complexity
65.6% medium
0.4% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$9,790
Total received (2018-2024)
Avg $1,399/year across 7 years
Top 43% in FL for rheumatology
39
Companies
501
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$9,790 (100.0%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$2,917
2023
$2,952
2022
$2,285
2021
$351
2020
$78
2019
$593
2018
$614

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Janssen Biotech, Inc.
$1,633
Novartis Pharmaceuticals Corporation
$1,255
Amgen Inc.
$926
UCB, Inc.
$760
ABBVIE INC.
$704
PFIZER INC.
$697
GlaxoSmithKline, LLC.
$595
Lilly USA, LLC
$565
AstraZeneca Pharmaceuticals LP
$482
Aurinia Pharma U.S., Inc.
$417
E.R. Squibb & Sons, L.L.C.
$287
Horizon Therapeutics plc
$244
Fresenius Kabi USA, LLC
$157
Regeneron Healthcare Solutions, Inc.
$137
Radius Health, Inc.
$110
Boehringer Ingelheim Pharmaceuticals, Inc.
$104
Takeda Pharmaceuticals U.S.A., Inc.
$88
AbbVie Inc.
$83
Janssen Scientific Affairs, LLC
$62
Celgene Corporation
$59
Organon Llc
$59
Kiniksa Pharmaceuticals International, plc
$37
Genentech USA, Inc.
$33
GENZYME CORPORATION
$30
Merck Sharp & Dohme Corporation
$27
Mylan Institutional Inc.
$25
Nabriva Therapeutics, plc
$23
TerSera Therapeutics LLC
$21
Mallinckrodt Hospital Products Inc.
$20
Exeltis, USA Inc.
$19
Novo Nordisk Inc
$19
Sandoz Inc.
$19
Pacira Pharmaceuticals Incorporated
$17
Sobi, Inc
$17
Actelion Pharmaceuticals US, Inc.
$16
SANOFI PASTEUR INC.
$12
Teva Pharmaceuticals USA, Inc.
$11
West-Ward Pharmaceuticals
$11
Sebela Pharmaceuticals Inc.
$11
Top 3 companies account for 39.0% of total payments
Associated products mentioned in payments ›
ACTHAR · AJOVY · AMJEVITA · Actemra · Aimovig · Arcalyst · BENLYSTA · BEVESPI AEROSPHERE · Bimzelx · CHANTIX · COLOGUARD · COSENTYX · CYLTEZO · Cimzia · ENTRESTO · EVENITY · EVUSHELD · Enbrel · FLUZONE QUADRIVALENT · HUMIRA · HYRIMOZ · IDACIO · ILARIS · INFLECTRA · Iovera · JANUVIA · JARDIANCE · KEVZARA · KEVZARA SARILUMAB INJECTION · KINERET · KRYSTEXXA · LUPKYNIS · Mitigare · NUCALA · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OFEV · OPSUMIT · ORENCIA · Otezla · PNEUMOVAX 23 · PURIFIED CORTROPHIN GEL · Prolia · Quzyttir · REMICADE · RENFLEXIS · RIDAURA · RINVOQ · SAPHNELO · SIMPONI ARIA · SKYRIZI · SPEVIGO · SYMBICORT · Saxenda · TALTZ · TAVNEOS · TREMFYA · TRULICITY · Trintellix · Tymlos · XELJANZ · Xenleta
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Equivalent to $4 per 100 Medicare services performed
Looking for a rheumatology specialist in Bradenton?
Compare rheumatologists in the Bradenton area by procedure volume, costs, and industry payment transparency.
Browse rheumatologists nearby

Geographic Context

Rheumatologists within 10 mi
35
Per 100K population
8.4
County median income
$75,792
Nearest hospital
HCA FLORIDA BLAKE HOSPITAL
0.0 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Gordian is a mixed practice specialist, with above-average Medicare volume (top 4% in FL), with low-engagement industry engagement, with 18 years of NPI registration.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Gordian experienced with certolizumab injection (cimzia)?
Based on Medicare claims data, Dr. Gordian performed 90,800 certolizumab injection (cimzia) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Gordian receive payments from pharmaceutical companies?
Yes. Dr. Gordian received a total of $9,790 from 39 companies across 501 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Gordian's costs compare to other rheumatologists in Bradenton?
Dr. Gordian's average Medicare payment per service is $12. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Gordian) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →